Advaxis, Inc., (OTCBB:ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today that it has secured $10 million in equity financing from Magna Group, LLC through its flagship Equity Enhancement Program, with an additional $1.4 million in financial commitments from a combination of sources as detailed below.

In addition, hidden under the radar of the first news, there was more news this morning that went under the radar. Trial data is very impressive! Advaxis clearly surpasses others in 12 month survival.

[The National Comprehensive Cancer Network Guidelines cite historical 12 month
survival data of 0-22% with single agent therapy in recurrent cervical cancer.
This study shows 12 month survival of 33% among a group of 70 patients.]